Literature DB >> 10685573

Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.

S Bielamowicz1, C L Ludlow.   

Abstract

To determine the mechanism of symptom relief with treatment by botulinum toxin injection in persons with adductor spasmodic dysphonia (ADSD), we evaluated the effects of unilateral thyroarytenoid muscle injections on both injected and noninjected muscles in 10 subjects with ADSD, using electromyography on both sides of the larynx before and after treatment. The subjects' speech symptoms were reduced (p = .005) 2 weeks following injection, when the electromyographic study occurred. Muscle activation levels and the numbers of spasmodic muscle bursts decreased significantly (p < or = .03) postinjection in both the injected and noninjected muscles. The reductions in laryngeal muscle bursts correlated with symptom reduction (r > or = .7) in all muscles. Reductions in laryngeal muscle bursts did not relate to either absolute or normalized levels of muscle activity before or after botulinum toxin injection. The results suggest that changes in the central pathophysiology are responsible for changes in speech symptoms following treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10685573     DOI: 10.1177/000348940010900215

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  21 in total

1.  Abnormal striatal dopaminergic neurotransmission during rest and task production in spasmodic dysphonia.

Authors:  Kristina Simonyan; Brian D Berman; Peter Herscovitch; Mark Hallett
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

Review 2.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Abnormal structure-function relationship in spasmodic dysphonia.

Authors:  Kristina Simonyan; Christy L Ludlow
Journal:  Cereb Cortex       Date:  2011-06-10       Impact factor: 5.357

4.  Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.

Authors:  Monika Rudzińska; Magdalena Wójcik; Andrzej Szczudlik
Journal:  J Neural Transm (Vienna)       Date:  2010-05-14       Impact factor: 3.575

Review 5.  Central voice production and pathophysiology of spasmodic dysphonia.

Authors:  Niv Mor; Kristina Simonyan; Andrew Blitzer
Journal:  Laryngoscope       Date:  2017-05-23       Impact factor: 3.325

Review 6.  Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience.

Authors:  Andrew Blitzer; Mitchell F Brin; Kristina Simonyan; Laurie J Ozelius; Steven J Frucht
Journal:  Laryngoscope       Date:  2017-12-08       Impact factor: 3.325

7.  Cortical sensorimotor alterations classify clinical phenotype and putative genotype of spasmodic dysphonia.

Authors:  G Battistella; S Fuertinger; L Fleysher; L J Ozelius; K Simonyan
Journal:  Eur J Neurol       Date:  2016-06-27       Impact factor: 6.089

Review 8.  Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs.

Authors:  C R Watts; D D Truong; C Nye
Journal:  J Neural Transm (Vienna)       Date:  2007-06-14       Impact factor: 3.575

9.  Evaluation of type II thyroplasty on phonatory physiology in an excised canine larynx model.

Authors:  Erin E Devine; Matthew R Hoffman; Timothy M McCulloch; Jack J Jiang
Journal:  Laryngoscope       Date:  2016-05-25       Impact factor: 3.325

10.  Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.

Authors:  Tahwinder Upile; Behrad Elmiyeh; Waseem Jerjes; Vyas Prasad; Panagiotis Kafas; Jesuloba Abiola; Bryan Youl; Ruth Epstein; Colin Hopper; Holger Sudhoff; John Rubin
Journal:  Head Face Med       Date:  2009-10-24       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.